Entera Bio Ltd. Ordinary Shares (ENTX) Dividend History

Entera Bio Ltd. (ENTX) is a biopharmaceutical company focused on developing oral biologic therapies for serious medical conditions. Leveraging its proprietary platform, the company aims to deliver biologic drugs that can be administered orally, offering potential advantages over traditional injectable treatments. Entera Bio’s pipeline includes candidates targeting osteoporosis, hormone deficiencies, and other indications, with an emphasis on improving patient compliance and convenience.

Kiryat Hadassah, Minrav Building, Jerusalem, L3, 9112002
Phone: 972-2-532-7151
Website: https://www.enterabio.com

Dividend History

Entera Bio Ltd. Ordinary Shares currently does not pay dividends

Company News

OPKO Health and Entera Bio Enter into Collaboration Agreement to Advance Oral GLP-1/Glucagon Tablet Candidate into the Clinic to Treat Obesity and Metabolic Disorders

OPKO Health and Entera Bio have entered into a collaboration agreement to advance an oral GLP-1/Glucagon dual agonist tablet into clinical trials for the treatment of obesity and metabolic disorders.

GlobeNewswire Inc.

Featured Companies: OPK
AbbVie (ABBV) Skyrizi Gets CHMP Nod for Ulcerative Colitis in EU

AbbVie (ABBV) announces that the EMA's CHMP issued a positive opinion on its regulatory filing seeking label expansion for the immunology drug, Skyrizi, to treat UC.

Zacks Investment Research

Featured Companies: ABBV ALXO ANVS
Has Entera Bio (ENTX) Outpaced Other Medical Stocks This Year?

Here is how Entera Bio Ltd. (ENTX) and PetIQ (PETQ) have performed compared to their sector so far this year.

Zacks Investment Research
Ultragenyx (RARE) DTX401 Meets Goals in Metabolic Disorder Study

Ultragenyx (RARE) reports meeting primary and secondary endpoints in the late-stage study of its investigational gene therapy, DTX401, to treat glycogen storage disease type Ia.

Zacks Investment Research

Featured Companies: ALXO ANVS RARE
Immunovant (IMVT) Falls as Q4 Earnings Miss, Pipeline in Focus

Immunovant (IMVT) declines 5% on dismal fourth-quarter fiscal 2024 results. The company names IMVT-1402 as its new lead candidate to initiate several studies for autoimmune indications.

Zacks Investment Research

Featured Companies: ALXO BHVN IMVT

Dividend data last updated 06/07/2025 20:38:44 UTC